MIT Sloan Management Review Announces in One of the Largest Ever Studies of Corporate Culture the 2020 Culture Champions

0 Comments

The Culture Champions list comes out of the Culture 500, a large-scale, interactive research study conducted by researchers at the MIT Sloan School of Management. Studying over 1.4 million Glassdoor reviews from more than 500 of the largest employers in the United States, the Culture 500 is notable for its large scale — it is one of the largest studies of corporate culture ever conducted — and use of groundbreaking AI technology developed at MIT to make sense of over a million employee reviews.

The standout organizations in the study, the 21 Culture Champions were recognized because their employees speak significantly more positively about a range of important cultural issues — including collaboration, integrity, and innovation — than their industry peers. They also exceed thresholds for diversity, integrity, and respect.

“In this year’s Culture 500, we reveal the 21 standout companies that jump off the page from our years of research at MIT,” said author and lead researcher Donald Sull. “When it comes to corporate culture, these Culture Champions walk the talk, unlike most companies we have studied, including some of the biggest household name companies.”

The 2020 Culture Champions Are:

Accenture

HP Inc.

Bain & Company

HubSpot

BlackRock

Mastercard

Boston Scientific

Netflix

Bristol Myers Squibb

Nvidia

CDW

Nordstrom

Chick-fil-A

St. Jude Children’s Hospital

The Clorox Company

Toyota Motor North America

Cummins

Trader Joe’s

Discount Tire

Ultimate Software

Hilton


“A culture of shared success is critical for who we want to be and what we want to do as a company,” said Julie Sweet, chief executive officer, Accenture, one of the companies named as a champion. “By embracing inclusion, diversity, and equality, we can attract the very best talent, unlock greater collaboration and innovation, and create value that benefits all of our stakeholders. We are honored

Preliminary results of two large immune therapy studies show promise in advanced cervical cancer — ScienceDaily

0 Comments

Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women.

David O’Malley, MD, of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), presented the preliminary study results at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 on Sept. 18. O’Malley was the lead presenter for both trials, which were sponsored by Agenus Inc.

Each study involved more than 150 patients with recurrent or metastatic cervical cancer from cancer treatment centers across the United States and Europe. All patients were previously treated with platinum-based chemotherapy as a first-line therapy. The two independent but consecutive phase II trials tested a new immune-based agent called balstilimab given alone or in combination with a second monoclonal antibody drug called zalifrelimab.

Balstilimab is part of a class of drugs called checkpoint inhibitors. These drugs target the PD-1 protein within cancer cells and act as an “on” switch to help the immune system recognize and destroy cancer cells that would otherwise go undetected. Zalifrelimab is a drug that delivers engineered molecules (monoclonal antibodies) that allow for improved immune response to attack cancer cells.

For the first study, 160 patients were treated with single-agent balstilimab, resulting in a 14% response rate in all treated patients and a 19% response rate in PD-L1 positive patients.

For the second study, 155 patients were treated with balstilimab given in combination with zalifrelimab, resulting in a 22% response rate in all patients and a 27% response rate in PD-L1 positive patients.

“These two studies represent the largest trials of immuno-oncology therapies in

Potomac Institute for Policy Studies Promotes Dr. Jennifer Buss to Chief Executive Officer and General Al Gray to Chairman, Board of Directors

0 Comments

ARLINGTON, Va., Oct. 5, 2020 /PRNewswire/ — The Board of Directors of the Potomac Institute for Policy Studies is pleased to announce the promotion of Dr. Jennifer Buss to Chief Executive Officer, and selection of General Al Gray as the new Chairman of the Board. Dr. Buss will immediately assume all duties and responsibilities that accompany the CEO position at the Institute. She was also named a member of the Board of Directors.

“I am incredibly humbled and honored to lead the Institute. I’ve been invested in its mission since I arrived,” Dr. Buss said. “I am committed to progressing the Institute and its contributions to policy in ever-changing science and technology.”

Dr. Buss replaces Mike Swetnam, who passed away in September. “Mike challenged and inspired me every day. It is because of his mentoring, and the leadership of General Al Gray, that I am ready for this new opportunity.”

Since joining the Institute as Research Fellow in 2012, Dr. Buss has written and won dozens of proposals, created several new centers, and in her most recent role as President, Dr. Buss has overseen all day-to-day business and operating functions of the Institute. She also previously served as Assistant Vice President and Vice President. Dr. Buss said, “I am grateful to the Board for having the confidence in my work and abilities to select me for this role. I look forward to proving my worth every day to them, our customers, and our team.” Dr. Buss earned her B.S. in Biochemistry with a minor in Mathematics from the University of Delaware, and a Ph.D. in Biochemistry from the University of Maryland.

“Dr. Buss has proven herself as a leader with a savvy mind for business. I’ve seen her grow the Institute and grow with it. She is responsible for the

University of Washington studies future of urban package delivery with lockers and street sensors

0 Comments

Fed up with porch pirates snatching your packages? Missed yet another delivery that requires a signature because you couldn’t hear the delivery person knock over your umpteenth video meeting of the day? Property manager at your apartment or condo building sending yet another nagging note to pick up packages because the mailroom is full?



This locker in Seattle’s Belltown neighborhood is part of a larger study of deliveries and urban mobility. (University of Washington Urban Freight Lab Photo)


© Provided by Geekwire
This locker in Seattle’s Belltown neighborhood is part of a larger study of deliveries and urban mobility. (University of Washington Urban Freight Lab Photo)

The newly installed. bright blue Belltown Lockers tucked into a parking lot at Fourth Avenue and Bell Street in Seattle may offer a safe haven for your deliveries — and chart the future of urban package delivery.

Loading...

Load Error

The lockers, which arrived in Seattle’s Belltown neighborhood in late August, come courtesy of the U.S. Department of Energy, which awarded the University of Washington’s Urban Freight Lab $1.5 million over three years to study how new technology might improve the energy efficiency of goods delivery in dense urban areas. Now two years into the study, the UW lab, which focuses on supply chain and transportation logistics in cities, has something for the public to try out so that researchers can study consumer behavior and package delivery patterns.

To participate, sign up for free as a locker customer, and the next time you order a package for delivery from any courier, set the address as “Republic Parking Locker, 314 Bell St., Seattle, WA 98121.” (REEF Technology, the Miami-based company behind the ghost kitchen craze, owns the lot.) When the package arrives, you will receive a notification on your phone. You can then use your phone to unlock the appropriate locker and retrieve the package. (Two lockers already exist in private buildings; a second public locker was recently approved for

Bruker Announces Acquisition of Integrated Proteomics Pipeline (IP2) Software Platform for Large Cohort Translational Studies

0 Comments

IP2 Accelerates CCS-enabled 4D-Proteomics™ with GPU-based Scalable Search Engine

IP2 Adds ‘Run & Done’ Real-Time Capabilities to timsTOF® Proteomics Systems

Bruker Corporation (Nasdaq: BRKR) announces the recent acquisition of the Integrated Proteomics Pipeline (IP2) search engine and proteomics workflow software platform. IP2 was developed by Integrated Proteomics Applications Inc, a company founded by leading proteomics researcher Professor John Yates III, together with Drs. Robin Park and Tao Xu. Financial details of the transaction were not disclosed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005135/en/

Prof. John Yates III, The Scripps Research Institute (Photo: Business Wire)

This acquisition further enhances Bruker’s solutions for CCS-enabled 4D-Proteomics™ by adding fast, scalable and GPU-based search engine capabilities for faster data processing and full utilization of molecular collision cross sections (CCS). Benefits include greater data completeness and higher confidence in protein and PTM identification and quantification in unbiased ‘shot-gun’ proteomics. Bruker’s novel timsTOF mass spectrometry systems with >120 Hz duty cycle in PASEF mode are uniquely suitable for real-time search by GPU-enabled, parallel operations on multiple threads.

“Partnering with the IP2 team and the Yates Lab provides an excellent opportunity to enhance Bruker’s bioinformatics capabilities in support of 4D-Proteomics™,” said Dr. Rohan A. Thakur, Bruker’s Executive Vice President for Life Science Mass Spectrometry. “High-throughput proteomics requires unprecedented search engine performance, including the need for low false discovery rates with very large datasets. This will benefit the proteomics research and translational medical community. We are also pleased to announce the establishment of Bruker’s bioinformatics team focused on protein and data science based in San Diego, California, headed by Robin Park who joined Bruker as part of the IP2 asset acquisition. Robin will continue to work closely with the Yates Lab in his new role with Bruker, as well as with other